Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 2/20 | 0.55 |
| ▸ | FEN1 | P39748 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886371 | 0.94 | ERCC5 (0.55) | ERCC5FEN1MAPTTP53PPARG | |
| SCHEMBL1897399 | 0.78 | CFTR (0.47) | ERCC5FEN1MAPTLMNAHPGD | |
| SCHEMBL1888266 | 0.72 | POLB (0.68) | MAPTTP53POLBEDNRB | |
| SCHEMBL1887988 | 0.71 | FEN1 (1.00) | ERCC5FEN1MAPTLMNAPPARG | |
| SCHEMBL1885513 | 0.70 | ERCC5 (0.46) | ERCC5FEN1POLBMAPK8 | |
| SCHEMBL4397609 | 0.63 | HDAC1 (0.46) | MAPTLMNATP53THRBPOLB | |
| SCHEMBL4397339 | 0.62 | P2RX4 (0.49) | MAPTLMNATP53THRBPOLB | |
| SCHEMBL5504492 | 0.61 | MAPT (0.82) | MAPTLMNATP53PPARGPPARD | |
| SCHEMBL30527861 | 0.61 | MAPT (0.82) | MAPTLMNATP53PPARGPPARD | |
| SCHEMBL12390180 | 0.61 | IDH1 (0.47) | MAPTLMNATP53THRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | claimed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | FEN1, UNG, POLH | ERCC5 73/4885FEN1 1/4885MAPT 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.